期刊
NEW BIOTECHNOLOGY
卷 28, 期 5, 页码 511-517出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nbt.2011.03.020
关键词
-
资金
- NIH [AG032611, AG020197, DK075494]
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation/Association for Frontotemporal Dementia
- Irma T. Hirschl/Monique Weill-Caulier Trust
Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease, Huntington's disease (HD) or amyotrophic lateral sclerosis (ALS) are all characterised histologically by the presence of deposits of misfolded proteins, tau and amyloid-beta, alpha-synuclein, huntingtin or superoxide dismutase, respectively. Currently, these illnesses do not have any disease modifying treatment options. A novel therapeutic strategy that is being pursued is immunomodulation, which is using the body's immune system to target the self-proteins that are deposited. Most of these promising approaches are still in preclinical development while some have progressed to Phase III clinical trials. As new insights are gained, it is hoped that these immunotherapies will be effective tools at slowing the progression of these debilitating diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据